
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Managing T-DXd ILD and treatment decisions
Haley Ellis and Eric Van Cutsem advise monitoring ILD, reassessing HER2 status after toxicity, and considering non‑ADC options.
Play episode from 17:08
Transcript


